全文获取类型
收费全文 | 165673篇 |
免费 | 14146篇 |
国内免费 | 8712篇 |
专业分类
耳鼻咽喉 | 583篇 |
儿科学 | 5501篇 |
妇产科学 | 2631篇 |
基础医学 | 15723篇 |
口腔科学 | 1903篇 |
临床医学 | 14018篇 |
内科学 | 31275篇 |
皮肤病学 | 1422篇 |
神经病学 | 6750篇 |
特种医学 | 5068篇 |
外国民族医学 | 27篇 |
外科学 | 28878篇 |
综合类 | 28456篇 |
现状与发展 | 34篇 |
一般理论 | 8篇 |
预防医学 | 8413篇 |
眼科学 | 3087篇 |
药学 | 16560篇 |
104篇 | |
中国医学 | 10446篇 |
肿瘤学 | 7644篇 |
出版年
2024年 | 284篇 |
2023年 | 2456篇 |
2022年 | 3394篇 |
2021年 | 5834篇 |
2020年 | 5829篇 |
2019年 | 5582篇 |
2018年 | 5482篇 |
2017年 | 5685篇 |
2016年 | 6133篇 |
2015年 | 5721篇 |
2014年 | 9968篇 |
2013年 | 11432篇 |
2012年 | 9203篇 |
2011年 | 10625篇 |
2010年 | 8659篇 |
2009年 | 8268篇 |
2008年 | 8451篇 |
2007年 | 8771篇 |
2006年 | 8335篇 |
2005年 | 7238篇 |
2004年 | 5998篇 |
2003年 | 5514篇 |
2002年 | 4459篇 |
2001年 | 4054篇 |
2000年 | 3366篇 |
1999年 | 2839篇 |
1998年 | 2563篇 |
1997年 | 2370篇 |
1996年 | 2182篇 |
1995年 | 1977篇 |
1994年 | 1851篇 |
1993年 | 1389篇 |
1992年 | 1450篇 |
1991年 | 1180篇 |
1990年 | 1037篇 |
1989年 | 912篇 |
1988年 | 802篇 |
1987年 | 633篇 |
1986年 | 646篇 |
1985年 | 886篇 |
1984年 | 798篇 |
1983年 | 526篇 |
1982年 | 653篇 |
1981年 | 528篇 |
1980年 | 506篇 |
1979年 | 379篇 |
1978年 | 337篇 |
1977年 | 300篇 |
1976年 | 292篇 |
1975年 | 166篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
31.
32.
复杂性胸壁缺损的修复一直是一项极具挑战性的工作。肿瘤性复杂性胸壁缺损的修复决策及其执行困难是限制胸壁肿瘤治疗方法选择及影响预后的重要因素之一。皮瓣解剖学研究的深入、胸壁支持结构重建技术的进步、显微外科技术的发展、麻醉护理的发展、对综合治疗的重视和治疗手段的进步等,使传统认为不可切除的胸壁肿瘤得以彻底地切除和安全有效地修复,从而使与缺损修复相关的肿瘤切除及辅助治疗的禁忌证缩减到最小程度,有效地提高了胸壁肿瘤患者的生存质量,并很大程度上延长了生存率。作者以湖南省肿瘤医院整形外科15年565例胸壁肿瘤切除后修复重建的临床资料为依据,充实了胸壁肿瘤切除及修复的策略:(1)可靠的胸壁骨性支架重建;(2)有效的软组织修复;(3)麻醉及护理与手术团队的合作;(4)系统有序的综合治疗。并进一步明确了复杂胸壁肿瘤切除及重建的细节理念,包括胸部肿瘤治疗中加强多学科合作的密切性和科学性,整形外科医生参与肿瘤治疗整体规划的主动性和时机前移等。 相似文献
33.
Osric A. Forrest Daniel M. Chopyk Yael Gernez Milton R. Brown Carol K. Conrad Richard B. Moss Vin Tangpricha Limin Peng Rabindra Tirouvanziam 《Journal of cystic fibrosis》2019,18(1):64-70
Background
Resistin is an immunometabolic mediator that is elevated in several inflammatory disorders. A ligand for Toll-like receptor 4, resistin modulates the recruitment and activation of myeloid cells, notably neutrophils. Neutrophils are major drivers of cystic fibrosis (CF) lung disease, in part due to the release of human neutrophil elastase- and myeloperoxidase-rich primary granules, leading to tissue damage. Here we assessed the relationship of resistin to CF lung disease.Methods
Resistin levels were measured in plasma and sputum from three retrospective CF cohorts spanning a wide range of disease. We also assessed the ability of neutrophils to secrete resistin upon activation in vitro. Finally, we constructed a multivariate model assessing the relationship between resistin levels and lung function.Results
Plasma resistin levels were only marginally higher in CF than in healthy control subjects. By contrast, sputum resistin levels were very high in CF, reaching 50–100 fold higher levels than in plasma. Among CF patients, higher plasma resistin levels were associated with allergic bronchopulmonary aspergillosis, and higher sputum resistin levels were associated with CF-related diabetes. Mechanistically, in vitro release of neutrophil primary granules was concomitant with resistin secretion. Overall, sputum resistin levels were negatively correlated with CF lung function, independently of other variables (age, sex, and genotype).Conclusions
Our data establish relationships between resistin levels in the plasma and sputum of CF patients that correlate with disease status, and identify resistin as a novel mechanistic link between neutrophilic inflammation and lung disease in CF. 相似文献34.
35.
36.
37.
《Journal of the American College of Radiology》2020,17(10):1207-1219
PurposeLobular neoplasia (LN) detected on breast core needle biopsy is frequently managed with surgical excision because of concern for undersampled malignancy. The authors performed a systematic review and meta-analysis to estimate the risk for upgrade to malignancy in the setting of imaging-concordant classic LN diagnosed on core biopsy.MethodsPubMed and Embase were searched for original articles published from 1998 to 2020 that reported rates of upgrade to malignancy for classic LN, including atypical lobular hyperplasia (ALH) and classic lobular carcinoma in situ (LCIS). Two reviewers extracted study data and assessed the following quality criteria: exclusion of variant LCIS, exclusion of imaging-discordant lesions, and outcome reporting for ≥70% of lesions. For studies meeting all criteria, pooled risks for upgrade to any malignancy (invasive carcinoma or ductal carcinoma in situ) and invasive malignancy for all LN, ALH, and LCIS were estimated using random-effects models.ResultsFor 65 full-text articles included in the review, the risk for upgrade to any malignancy ranged from 0% to 45%. Among the 16 studies that met all quality criteria for the meta-analysis, pooled risks for upgrade to any malignancy were 3.1% (95% confidence interval [CI], 1.8%-5.2%) for all LN, 2.5% (95% CI, 1.6%-3.9%) for ALH, and 5.8% (95% CI, 2.9%-11.3%) for LCIS. Risks for upgrade to invasive malignancy were 1.3% (95% CI, 0.7%-2.4%) for all LN, 0.4% (95% CI, 0.0%-4.2%) for ALH, and 3.5% (95% CI, 2.0%-5.9%) for LCIS.ConclusionsThe risk for upgrade to malignancy for LN found on breast biopsy is low. Imaging surveillance can likely be offered as an alternative to surgical management for LN, particularly for ALH. 相似文献
38.
Yesim Aydinok 《ISBT科学丛刊》2020,15(1):102-109
Lifetime red cell concentrate (RCC) transfusions still account for significant iron overload‐related morbidity and mortality despite chelation therapy in thalassaemia. The cumulative risk of transfusion‐transmitted infections is substantial for thalassaemia patients. Pathogen reduction technologies for RCC may imply a proactive approach against new/re‐emerging pathogens and may be an ultimate safeguard for transfusion safety in the developing countries. Red cell alloimmunization may become a significant clinical challenge in thalassaemia. The availability of high‐throughput molecular blood group antigen typing in the donors may allow perfect match transfusion, beyond ABO‐D and CEK antigen‐matched transfusions. Allogeneic stem cell transplantation (A‐SCT) is the only available curative therapy in thalassaemia, but carries a substantial risk of serious adverse events and mortality. Gene addition therapy for correction of the α‐globin chain imbalance overcomes the problems of donor availability and immunological complications of A‐SCT. Gene editing by either gene disruption or correction emerged as a potential alternative to gene addition therapy in beta‐thalassaemia. A new era of novel therapeutics targeting α/β imbalance, ineffective erythropoiesis or iron dysregulation is unfolding in thalassaemia management, and a number of those now have agents in preclinical and clinical development. Hydroxyurea (HU) may improve globin chain imbalance and be beneficial for reducing or omitting transfusion requirement. Ruxolitinib has allowed steady decrease in spleen volume that may serve for avoiding splenectomy in beta‐thalassaemia. Luspatercept may restore normal erythroid differentiation and improve anaemia. Hepcidin mimetics or TMPRSS6 inhibitors may modulate ineffective erythropoiesis by iron restriction and improve anaemia and organ iron loading. 相似文献
39.
40.
仝小林院士将新型冠状病毒肺炎定名为"寒湿疫",并以此理论为基础制定了初期、中期、重症期及恢复期的中医治疗方案,同时基于仝院士学术理论体系中的"脏腑风湿"理论,根据恢复期 "余毒未清,正虚邪恋"的病机特点,探讨其符合具备脏腑风湿行成3个基本要素:即外受寒湿裹挟戾气为必要外因;脏腑内虚为重要基础;邪疫伏留胶着,正邪交争为致病关键。故在辨证施治中可应用脏腑风湿理论以调理脾胃,化湿透邪,补益肺脾,顾护阳气,养阴生津。 相似文献